Advertisement

Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations

Published:January 27, 2020DOI:https://doi.org/10.1016/j.amepre.2019.10.022

      Introduction

      Recommending both the conjugate and polysaccharide pneumococcal vaccines to all U.S. seniors may have little public health impact and be economically unreasonable. Public health impact and cost-effectiveness of using both vaccines in all adults aged ≥65 years were estimated compared with an alternative strategy (omitting pneumococcal conjugate vaccine in the nonimmunocompromised) and with the newly revised recommendation (giving or omitting conjugate vaccine based on patient–physician shared decision making).

      Methods

      Strategies were examined in hypothetical U.S. 65-year-old population cohorts and segmented into health states based on age- and population-specific data in a Markov state-transition model with a lifetime time horizon from a healthcare perspective. Black population cohorts were examined separately given greater illness risk and lower vaccine uptake. Model parameters came from the Centers for Disease Control Active Core Bacterial Surveillance network, National Health Interview Survey, and Nationwide Inpatient Sample data. Outcomes included incremental costs per quality-adjusted life year gained and pneumococcal disease outcomes for each strategy. Data were gathered and analysis performed in 2018.

      Results

      Giving both vaccines, either routinely or with shared decision making, was most effective, reducing pneumococcal disease incidence compared with no vaccination, but costing $765,000–$2.18 million/quality-adjusted life year gained. Depending on examined population and scenario, the alternative strategy cost $65,700–$226,700/quality-adjusted life year gained (less in black populations) and reduced cases and deaths by 0.3%–0.9%.

      Conclusions

      A vaccination strategy that omits pneumococcal conjugate vaccine in immunocompetent U.S. seniors may be economically reasonable, particularly for black seniors. Use of both pneumococcal vaccines was more effective but substantially more expensive.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Moore MR
        • Link-Gelles R
        • Schaffner W
        • et al.
        Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
        Lancet Infect Dis. 2015; 15: 301-309
        • Bonten MJM
        • Huijts SM
        • Bolkenbaas M
        • et al.
        Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
        N Engl J Med. 2015; 372: 1114-1125
        • Stoecker C
        • Kim L
        • Gierke R
        • Pilishvili T
        Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States.
        J Gen Intern Med. 2016; 31: 901-908
        • Tomczyk S
        • Bennett NM
        • Stoecker C
        • et al.
        Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Morb Mortal Wkly Rep. 2014; 63: 822-825
      1. Matanock A. Considerations for PCV13 use among adults >65 years old and a summary of the evidence to recommendations framework. Advisory Committee on Immunization Practices, June 2019 Meeting.www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-06/Pneumococcal-2-Matanock-508.pdf. Updated August 29, 2019. Accessed November 5, 2019.

        • Smith KJ
        • Wateska AR
        • Nowalk MP
        • Raymund M
        • Nuorti JP
        • Zimmerman RK
        Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
        JAMA. 2012; 307: 804-812
        • Pilishvili T
        Impact of PCV13 on Invasive Pneumococcal Disease (IPD) Burden and the Serotype Distribution in the U.S.
        Advisory Committee on Immunization Practices, Atlanta, GAPublished 2018
        https://stacks.cdc.gov/view/cdc/61449
        Date accessed: November 11, 2019
        • Williams WW
        • Lu PJ
        • O'Halloran A
        • et al.
        Surveillance of vaccination coverage among adult populations - United States, 2015.
        MMWR Surveill Summ. 2017; 66: 1-28
        • Kyaw MH
        • Rose CE
        • Fry AM
        • et al.
        The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults.
        J Infect Dis. 2005; 192: 377-386
      2. CDC. CDC vaccine price list. www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html. Updated September 1, 2019. Accessed September 25, 2019.

        • Kim EJ
        • Kim T
        • Conigliaro J
        • Liebschutz JM
        • Paasche-Orlow MK
        • Hanchate AD
        Racial and ethnic disparities in diagnosis of chronic medical conditions in the USA.
        J Gen Intern Med. 2018; 33: 1116-1123
        • Burton DC
        • Flannery B
        • Bennett NM
        • et al.
        Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults.
        Am J Public Health. 2010; 100: 1904-1911
        • Zimmerman RK
        • Lauderdale DS
        • Tan SM
        • Wagener DK
        Prevalence of high-risk indications for influenza vaccine varies by age, race, and income.
        Vaccine. 2010; 28: 6470-6477
        • Nowalk MP
        • Wateska AR
        • Lin CJ
        • et al.
        Racial disparities in adult pneumococcal vaccination indications and pneumococcal hospitalizations in the U.S.
        J Natl Med Assoc. 2019; 111: 540-545
        • See I
        • Wesson P
        • Gualandi N
        • et al.
        Socioeconomic factors explain racial disparities in invasive community-associated methicillin-resistant Staphylococcus aureus disease rates.
        Clin Infect Dis. 2017; 64: 597-604
        • Said MA
        • Johnson HL
        • Nonyane BAS
        • et al.
        Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques.
        PLoS One. 2013; 8: e60273
        • HHS, Centers for Medicare and Medicaid Services
        Physician fee schedule search. (CPT 90471).
        Data Year. 2017; (www.cms.gov/apps/physician-fee-schedule/. Updated February 1, 2018. Accessed November 11, 2019)
        • Anderson WL
        • Armour BS
        • Finkelstein EA
        • Wiener JM
        Estimates of state-level health-care expenditures associated with disability.
        Public Health Rep. 2010; 125: 44-51
        • Gold MR
        • Franks P
        • McCoy KI
        • Fryback DG
        Toward consistency in cost-utility analyses: using national measures to create condition-specific values.
        Med Care. 1998; 36: 778-792
        • Sisk JE
        • Whang W
        • Butler JC
        • Sneller VP
        • Whitney CG
        Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.
        Ann Intern Med. 2003; 138: 960-968
        • Mangen MJ
        • Huijts SM
        • Bonten MJ
        • de Wit GA
        The impact of community-acquired pneumonia on the health-related quality-of-life in elderly.
        BMC Infect Dis. 2017; 17: 208
        • Jackson LA
        • Benson P
        • Sneller VP
        • et al.
        Safety of revaccination with pneumococcal polysaccharide vaccine.
        JAMA. 1999; 281: 243-248
        • Smith KJ
        • Zimmerman RK
        • Lin CJ
        • et al.
        Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis.
        Vaccine. 2008; 26: 1420-1431
        • Grabenstein JD
        Effectiveness and serotype coverage: key criteria for pneumococcal vaccines for adults.
        Clin Infect Dis. 2012; 55: 255-258
        • Musher DM
        Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?.
        Clin Infect Dis. 2012; 55: 265-267
        • Harpaz R
        • Dahl RM
        • Dooling KL
        Prevalence of immunosuppression among US adults, 2013.
        JAMA. 2016; 316: 2547-2548
      3. HHS, CDC. Pneumococcal vaccine timing for adults. www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf. Updated November 30, 2015. Accessed September 25, 2019.

        • Fry AM
        • Zell ER
        • Schuchat A
        • Butler JC
        • Whitney CG
        Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly.
        Vaccine. 2002; 21: 303-311
        • Stoecker C
        Economic analysis of sustaining the current recommendation for PCV13 use among adults 65 years of older in the context of continued indirect effects from the pediatric PCV13 program.
        ACIP, Published October 2018
        • CDC
        Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae.
        Published 2017 (2017.)
        • Neumann PJ
        • Cohen JT
        • Weinstein MC
        Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold.
        N Engl J Med. 2014; 371: 796-797
        • van Hoek AJ
        • Miller E
        Cost-effectiveness of vaccinating immunocompetent ≥65 year olds with the 13-valent pneumococcal conjugate vaccine in England.
        PLoS One. 2016; 11e0149540
        • Thorrington D
        • van Rossum L
        • Knol M
        • et al.
        Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.
        PLoS One. 2018; 13e0192640
      4. Leidner AL. Overview of three economic analyses of pneumococcal vaccinations at age 65. Advisory Committee on Immunization Practices February 2019 meeting. www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-02/Pneumococcal-4-Leidner-508.pdf. Updated April 14, 2019. Accessed November 5, 2019.

        • Jain S
        • Self WH
        • Wunderink RG
        • et al.
        Community-acquired pneumonia requiring hospitalization among U.S. adults.
        N Engl J Med. 2015; 373: 415-427
        • Ramirez JA
        • Wiemken TL
        • Peyrani P
        • et al.
        Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality.
        Clin Infect Dis. 2017; 65: 1806-1812
        • Wateska AR
        • Nowalk MP
        • Lin CJ
        • et al.
        Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50‒64 years compared to the US general population.
        Vaccine. 2019; 37: 2026-2033
      5. Pilishvili T. 13-valent pneumococcal conjugate vaccine (PCV13) effects on disease caused by serotype 3. Advisory Committee on Immunization Practices February 2019 meeting. https://stacks.cdc.gov/view/cdc/78091. Updated April 16, 2019. Accessed November 11, 2019.